Mydecine Innovations Group Inc.

États‑Unis d’Amérique

Retour au propriétaire
1-34 de 34 pour Mydecine Innovations Group Inc. Trier par
Recheche Texte
Affiner par
Type PI
        Brevet 26
        Marque 8
Juridiction
        États-Unis 19
        International 9
        Canada 6
Date
2024 décembre 1
2024 7
2023 14
2022 11
2020 2
Classe IPC
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine 8
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur 6
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux 5
C07D 209/16 - Tryptamines 5
A61K 31/33 - Composés hétérocycliques 4
Voir plus
Classe NICE
42 - Services scientifiques, technologiques et industriels, recherche et conception 8
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture. 8
Statut
En Instance 14
Enregistré / En vigueur 20

1.

SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE

      
Numéro d'application 18227186
Statut En instance
Date de dépôt 2023-07-27
Date de la première publication 2024-12-05
Propriétaire Mydecine Innovations Group Inc. (USA)
Inventeur(s)
  • Hoyer, Denton W.
  • Roscow, Robert F.
  • Ling, Rong
  • Gao, Chuanjun

Abrégé

The present invention is directed to novel chemical compositions of matter, and in particular a novel MDMA class of compounds MDMA analogs having 1,3-benzothiazoles substituted at the 5 and 6-position with a MDMA basic or modified side chain.

Classes IPC  ?

  • C07D 277/62 - Benzothiazoles
  • A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

2.

NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS

      
Numéro d'application 18405189
Statut En instance
Date de dépôt 2024-01-05
Date de la première publication 2024-06-20
Propriétaire Mydecine Innovations Group Inc. (USA)
Inventeur(s)
  • Hoyer, Denton W.
  • Roscow, Robert F.
  • Ling, Rong
  • Gao, Chuanjun

Abrégé

The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

Classes IPC  ?

  • A61K 31/39 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des atomes d'oxygène dans le même cycle
  • A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
  • A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

3.

Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same

      
Numéro d'application 18443025
Statut En instance
Date de dépôt 2024-02-15
Date de la première publication 2024-06-20
Propriétaire Mydecine Innovations Group Inc. (USA)
Inventeur(s)
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abrégé

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

Classes IPC  ?

  • C07D 209/14 - Radicaux substitués par des atomes d'azote ne faisant pas partie d'un radical nitro
  • C07D 209/12 - Radicaux substitués par des atomes d'oxygène
  • C07D 209/16 - Tryptamines
  • C07D 471/04 - Systèmes condensés en ortho

4.

Aza-substituted psilocin analogs and methods of synthesizing the same

      
Numéro d'application 18386021
Numéro de brevet 11939292
Statut Délivré - en vigueur
Date de dépôt 2023-11-01
Date de la première publication 2024-03-26
Date d'octroi 2024-03-26
Propriétaire Mydecine Innovations Group Inc. (USA)
Inventeur(s)
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abrégé

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

Classes IPC  ?

  • C07D 209/14 - Radicaux substitués par des atomes d'azote ne faisant pas partie d'un radical nitro
  • C07D 209/12 - Radicaux substitués par des atomes d'oxygène
  • C07D 209/16 - Tryptamines
  • C07D 471/04 - Systèmes condensés en ortho

5.

SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE

      
Numéro de document 03232547
Statut En instance
Date de dépôt 2023-06-13
Date de disponibilité au public 2024-03-14
Propriétaire MYDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s)
  • Hoyer, Denton W.
  • Roscow, Robert F.
  • Ling, Rong
  • Gao, Chuanjun

Abrégé

The present invention is directed to novel chemical compositions of matter, and in particular a novel MDMA class of compounds MDMA analogs having 1,3-benzothiazoles substituted at the 5 and 6-position with a MDMA basic or modified side chain.

Classes IPC  ?

  • A61K 31/13 - Amines, p. ex. amantadine
  • A61K 31/33 - Composés hétérocycliques
  • A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
  • A61K 31/4743 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant le soufre comme hétéro-atome d'un cycle
  • C07D 263/54 - BenzoxazolesBenzoxazoles hydrogénés
  • C07D 263/52 - Composés hétérocycliques contenant des cycles oxazole-1, 3 ou oxazole-1, 3 hydrogéné condensés avec des carbocycles ou avec des systèmes carbocycliques

6.

SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE

      
Numéro d'application US2023025197
Numéro de publication 2024/054279
Statut Délivré - en vigueur
Date de dépôt 2023-06-13
Date de publication 2024-03-14
Propriétaire MYDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s)
  • Hoyer, Denton, W.
  • Roscow, Robert, F.
  • Ling, Rong
  • Gao, Chuanjun

Abrégé

The present invention is directed to novel chemical compositions of matter, and in particular a novel MDMA class of compounds MDMA analogs having 1,3-benzothiazoles substituted at the 5 and 6-position with a MDMA basic or modified side chain.

Classes IPC  ?

  • A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
  • A61K 31/4743 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant le soufre comme hétéro-atome d'un cycle
  • A61K 31/13 - Amines, p. ex. amantadine
  • C07D 263/54 - BenzoxazolesBenzoxazoles hydrogénés
  • A61K 31/33 - Composés hétérocycliques
  • C07D 263/52 - Composés hétérocycliques contenant des cycles oxazole-1, 3 ou oxazole-1, 3 hydrogéné condensés avec des carbocycles ou avec des systèmes carbocycliques

7.

PRODRUG COMPOUNDS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND METHODS OF SYNTHESIZING THE SAME

      
Numéro d'application 18226767
Statut En instance
Date de dépôt 2023-07-26
Date de la première publication 2024-01-18
Propriétaire Mydecine Innovations Group Inc. (USA)
Inventeur(s)
  • Hoyer, Denton W.
  • Roscow, Robert F.
  • Ling, Rong
  • Gao, Chuanjun

Abrégé

The present invention includes a novel class of MDMA carbamates that can be activated in vivo as prodrugs. The MDMA prodrugs of the invention are enzymatically cleaved in vivo and produce alcohols of low toxicity that are well tolerated and metabolized in humans.

Classes IPC  ?

  • C07D 317/58 - Radicaux substitués par des atomes d'azote
  • C07D 327/04 - Cycles à cinq chaînons
  • A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

8.

NOVEL FUNGAL COMPOIND FORMULATIONS AND THEIR THERAPEUTIC METHODS OF USE

      
Numéro d'application 18032922
Statut En instance
Date de dépôt 2021-10-28
Date de la première publication 2023-12-14
Propriétaire Mydecine Innovations Group Inc. (USA)
Inventeur(s) Roscow, Robert F.

Abrégé

The present invention further relates generally to novel systems, methods, and compositions for generating pharmaceutical compositions and formulations that include one or more fungal compounds and/or extracts.

Classes IPC  ?

  • A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
  • A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
  • A61K 36/068 - Cordyceps
  • A61K 36/074 - Ganoderma
  • A61K 36/07 - Basidiomycota, p. ex. Cryptococcus

9.

NOVEL PSYCHEDELIC COMPOSITIONS, DELIVERY SYSTEMS AND THERAPEUTIC USES THEREOF

      
Numéro d'application 18029543
Statut En instance
Date de dépôt 2021-10-01
Date de la première publication 2023-11-16
Propriétaire Mydecine Innovations Group Inc. (USA)
Inventeur(s)
  • Gustin, John C
  • Mccarthy, Michael J

Abrégé

The present invention provides compositions and methods for the treatment of a serotonin receptor related disease or condition in a subject in need thereof. A composition of the invention includes at least one psychedelic compound, which is preferably a serotonin receptor agonist, and at least one secondary agent that modulates the activity of the serotonin receptor agonist, or the physiological response to the serotonin receptor agonist in the subject.

Classes IPC  ?

  • A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
  • A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
  • A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
  • A61K 31/7042 - Composés ayant des radicaux saccharide et des hétérocycles
  • A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
  • A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
  • A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
  • A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
  • A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
  • A61K 31/277 - NitrilesIsonitriles ayant un cycle, p. ex. vérapamil
  • A61K 31/015 - Hydrocarbures carbocycliques
  • A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
  • A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
  • A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
  • A61K 31/4409 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 4, p. ex. isoniazide, iproniazide
  • A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
  • A61K 31/15 - Oximes (C=N-O-)Hydrazines ( N-N)Hydrazones (N-N=)
  • A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone
  • A61K 31/5375 - 1,4-Oxazines, p. ex. morpholine
  • A61K 31/421 - 1,3-Oxazoles, p. ex. pémoline, triméthadione

10.

NOVEL PSILOCIN PRODRUG COMPOUNDS AND METHODS OF SYNTHESIZING THE SAME

      
Numéro d'application US2023019714
Numéro de publication 2023/219789
Statut Délivré - en vigueur
Date de dépôt 2023-04-25
Date de publication 2023-11-16
Propriétaire MYDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s)
  • Hoyer, Denton, W.
  • Roscow, Robert, F.

Abrégé

in vivo. in vivo.

Classes IPC  ?

  • A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
  • A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
  • A61K 31/13 - Amines, p. ex. amantadine
  • A61K 31/33 - Composés hétérocycliques

11.

NOVEL PSILOCIN PRODRUG COMPOUNDS AND METHODS OF SYNTHESIZING THE SAME

      
Numéro de document 03224835
Statut En instance
Date de dépôt 2023-04-25
Date de disponibilité au public 2023-11-16
Propriétaire MYDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s)
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abrégé

The present invention includes a novel class of psilocin carbamates and carbonate prodrug compounds having one or more aza substitution within the psilocin core. The psilocin prodrugs of the invention are enzymatically cleaved in vivo.

Classes IPC  ?

  • A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine

12.

Aza-substituted psilocin analogs and methods of synthesizing the same

      
Numéro d'application 18142010
Numéro de brevet 11952342
Statut Délivré - en vigueur
Date de dépôt 2023-05-01
Date de la première publication 2023-11-02
Date d'octroi 2024-04-09
Propriétaire Mydecine Innovations Group Inc. (USA)
Inventeur(s)
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abrégé

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

Classes IPC  ?

  • C07D 209/16 - Tryptamines
  • C07D 209/12 - Radicaux substitués par des atomes d'oxygène
  • C07D 209/14 - Radicaux substitués par des atomes d'azote ne faisant pas partie d'un radical nitro
  • C07D 471/04 - Systèmes condensés en ortho

13.

Novel Formulations of Psilocybin And Psilocin Compounds as Serotonin Agonists in Combination With 3,4 Methylenedioxymethamphetamine (MDMA)

      
Numéro d'application 18026780
Statut En instance
Date de dépôt 2021-09-18
Date de la première publication 2023-11-02
Propriétaire Mydecine Innovations Group Inc. (USA)
Inventeur(s) Roscow, Robert Fletcher

Abrégé

The present invention is directed to the use of psilocybin and/or psilocin compounds in combination with 3,4-methylenedioxymethamphetamine (MDMA) or other entactogens, to modulate activity of serotonin receptors, and preferably the 5-HT2A serotonin receptor in humans. In certain preferred embodiment, the co-formulation of psilocybin and/or psilocin compounds in combination with MDMA may result in complex modulation activity of serotonin receptors in a subject in need thereof, and may be uses as a therapeutic treatment for one or more serotonin receptor related diseases or conditions.

Classes IPC  ?

  • A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
  • A61K 31/36 - Composés contenant des groupes méthylènedioxyphényle, p. ex. sésamine
  • A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine

14.

Short-acting psychoactive compounds of the MDMA class

      
Numéro d'application 18209334
Numéro de brevet 11896577
Statut Délivré - en vigueur
Date de dépôt 2023-06-13
Date de la première publication 2023-10-12
Date d'octroi 2024-02-13
Propriétaire Mydecine Innovations Group Inc. (USA)
Inventeur(s)
  • Hoyer, Denton W.
  • Roscow, Robert F.
  • Ling, Rong
  • Gao, Chuanjun

Abrégé

The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

Classes IPC  ?

  • A61K 31/39 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des atomes d'oxygène dans le même cycle
  • A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
  • A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

15.

NOVEL PRODRUG COMPOUNDS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND METHODS OF SYNTHESIZING THE SAME

      
Numéro de document 03218730
Statut En instance
Date de dépôt 2023-02-27
Date de disponibilité au public 2023-08-31
Propriétaire MYDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s)
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abrégé

The present invention includes a novel class ofMDMA carbamates that can be activated in vivo as prodrugs. The MDMA prodrugs of the invention are enzymatically cleaved in vivo and produce alcohols of low toxicity that are well tolerated and metabolized in humans.

Classes IPC  ?

  • C07D 317/60 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
  • A61K 31/36 - Composés contenant des groupes méthylènedioxyphényle, p. ex. sésamine

16.

Novel Psilocin Analog Compositions And Methods of Synthesizing The Same

      
Numéro d'application 18141844
Statut En instance
Date de dépôt 2023-05-01
Date de la première publication 2023-08-31
Propriétaire Mydecine Innovations Group Inc. (USA)
Inventeur(s)
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abrégé

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

Classes IPC  ?

  • C07D 209/14 - Radicaux substitués par des atomes d'azote ne faisant pas partie d'un radical nitro
  • C07D 209/12 - Radicaux substitués par des atomes d'oxygène

17.

NOVEL PRODRUG COMPOUNDS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND METHODS OF SYNTHESIZING THE SAME

      
Numéro d'application US2023013928
Numéro de publication 2023/164203
Statut Délivré - en vigueur
Date de dépôt 2023-02-27
Date de publication 2023-08-31
Propriétaire MYDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s)
  • Hoyer, Denton, W.
  • Roscow, Robert, F.

Abrégé

The present invention includes a novel class ofMDMA carbamates that can be activated in vivo as prodrugs. The MDMA prodrugs of the invention are enzymatically cleaved in vivo and produce alcohols of low toxicity that are well tolerated and metabolized in humans.

Classes IPC  ?

  • C07D 317/58 - Radicaux substitués par des atomes d'azote
  • A61K 31/36 - Composés contenant des groupes méthylènedioxyphényle, p. ex. sésamine
  • A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

18.

NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME

      
Numéro d'application US2022031945
Numéro de publication 2023/101722
Statut Délivré - en vigueur
Date de dépôt 2022-06-02
Date de publication 2023-06-08
Propriétaire MYDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s)
  • Hoyer, Denton, W.
  • Roscow, Robert, F.

Abrégé

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

Classes IPC  ?

  • A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
  • A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
  • A61K 31/33 - Composés hétérocycliques
  • A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques

19.

NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME

      
Numéro de document 03210114
Statut En instance
Date de dépôt 2022-06-02
Date de disponibilité au public 2023-06-08
Propriétaire MEDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s)
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abrégé

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

Classes IPC  ?

  • C07D 471/04 - Systèmes condensés en ortho
  • A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
  • A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

20.

NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS

      
Numéro de document 03209813
Statut En instance
Date de dépôt 2022-07-14
Date de disponibilité au public 2023-01-19
Propriétaire MYDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s)
  • Hoyer, Dr. Denton W.
  • Roscow, Robert F.

Abrégé

The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

Classes IPC  ?

  • C07D 333/58 - Radicaux substitués par des atomes d'azote
  • A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
  • A61K 31/39 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des atomes d'oxygène dans le même cycle
  • A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
  • C07D 327/04 - Cycles à cinq chaînons

21.

NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS

      
Numéro d'application US2022037193
Numéro de publication 2023/288013
Statut Délivré - en vigueur
Date de dépôt 2022-07-14
Date de publication 2023-01-19
Propriétaire MYDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s)
  • Hoyer, Dr., Denton, W.
  • Roscow, Robert, F.

Abrégé

The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

Classes IPC  ?

  • A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
  • A61K 31/39 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des atomes d'oxygène dans le même cycle
  • C07D 327/02 - Composés hétérocycliques contenant des cycles comportant des atomes de soufre et d'oxygène comme uniques hétéro-atomes du cycle un atome d'oxygène et un atome de soufre

22.

NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME

      
Numéro de document 03197923
Statut En instance
Date de dépôt 2021-12-03
Date de disponibilité au public 2022-06-09
Propriétaire MYDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s)
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abrégé

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

Classes IPC  ?

23.

NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME

      
Numéro d'application US2021061826
Numéro de publication 2022/120181
Statut Délivré - en vigueur
Date de dépôt 2021-12-03
Date de publication 2022-06-09
Propriétaire MYDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s)
  • Hoyer, Denton, W.
  • Roscow, Robert, F.

Abrégé

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

Classes IPC  ?

  • A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
  • A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
  • C07D 209/16 - Tryptamines

24.

NOVEL FUNGAL COMPOUND FORMULATIONS AND THEIR THERAPEUTIC METHODS OF USE

      
Numéro d'application US2021057017
Numéro de publication 2022/094054
Statut Délivré - en vigueur
Date de dépôt 2021-10-28
Date de publication 2022-05-05
Propriétaire MYDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s) Roscow, Robert, F.

Abrégé

The present invention further relates generally to novel systems, methods, and compositions for generating pharmaceutical compositions and formulations that include one or more fungal compounds and/or extracts.

Classes IPC  ?

25.

NOVEL PSYCHEDELIC COMPOSITIONS, DELIVERY SYSTEMS AND THERAPEUTIC USES THEREOF

      
Numéro d'application US2021053136
Numéro de publication 2022/072808
Statut Délivré - en vigueur
Date de dépôt 2021-10-01
Date de publication 2022-04-07
Propriétaire MYDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s)
  • Gustin, John C
  • Mccarthy, Michael J.

Abrégé

The present invention provides compositions and methods for the treatment of a serotonin receptor related disease or condition in a subject in need thereof. A composition of the invention includes at least one psychedelic compound, which is preferably a serotonin receptor agonist, and at least one secondary agent that modulates the activity of the serotonin receptor agonist, or the physiological response to the serotonin receptor agonist in the subject.

Classes IPC  ?

  • A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
  • A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
  • A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

26.

NOVEL FORMULATIONS OF PSILOCYBIN AND PSILOCIN COMPOUNDS AS SEROTONIN AGONISTS IN COMBINATION WITH 3,4 METHYLENEDIOXYMETHAMPHETAMINE (MDMA)

      
Numéro d'application US2021051005
Numéro de publication 2022/061196
Statut Délivré - en vigueur
Date de dépôt 2021-09-18
Date de publication 2022-03-24
Propriétaire MYDECINE INNOVATIONS GROUP INC. (USA)
Inventeur(s) Roscow, Robert, Fletcher

Abrégé

The present invention is directed to the use of psilocybin and/or psilocin compounds in combination with 3,4-methylenedioxymethamphetamine (MDMA) or other entactogens, to modulate activity of serotonin receptors, and preferably the 5-HT2A serotonin receptor in humans. In certain preferred embodiment, the co-formulation of psilocybin and/or psilocin compounds in combination with MDMA may result in complex modulation activity of serotonin receptors in a subject in need thereof, and may be uses as a therapeutic treatment for one or more serotonin receptor related diseases or conditions.

Classes IPC  ?

  • A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
  • A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
  • A61P 25/20 - HypnotiquesSédatifs
  • A61P 25/24 - Antidépresseurs
  • A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates

27.

MYDECINE MEDICINE EVOLVED

      
Numéro de série 97289862
Statut Enregistrée
Date de dépôt 2022-03-01
Date d'enregistrement 2023-03-28
Propriétaire Mydecine Innovations Group Inc ()
Classes de Nice  ?
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Biological research; Biological research and analysis; Biomedical research services; Chemical, biochemical, biological and bacteriological research and analysis; Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of pharmacogenetics; Development of pharmaceutical preparations and medicines; Genetic testing for scientific research purposes; Laboratory research in the field of mental health; Laboratory research in the field of mycology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of mental health; Medical and scientific research in the field of mycology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research services; Product research and development; Providing information about medical and scientific research; Providing information about medical research; Providing information about medical research in the field of mental health; Providing information about medical research in the field of mycology; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Quality control for others; Research and development in the field of mental health; Research and development in the field of mycology; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of technology in the field of mental health; Research and development of technology in the field of mycology; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific and technological services, namely, research and design in the field of mental health; Scientific and technological services, namely, research and design in the field of mycology; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mental health; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mycology; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research and development; Scientific research in the field of genetics and genetic engineering; Scientific research in the nature of conducting clinical trials for others in the field of mental health; Scientific research in the nature of conducting clinical trials for others in the field of mycology; Testing of pharmaceuticals Psychotherapy; Addiction treatment services; Advisory services relating to health care; Advisory services relating to health; Alternative medicine services; Clinical mental health counseling services; Consultancy services relating to health care; Drug use testing services; Health care; Health care consulting in the field of mental health; Health care services for treating mental health; Health care services, namely, providing a database in the field of mental health information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, providing a database in the field of mycology information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, pharmaceutical drug development services, medical research, biological research, product research and development and pharmaceutical research services; Health clinic services; Managed health care services; Medical services; Mental health services; Mental health therapy services; Providing mental health and wellness information; Psychotherapy services

28.

M MYDECINE MEDICINE EVOLVED

      
Numéro de série 97289912
Statut Enregistrée
Date de dépôt 2022-03-01
Date d'enregistrement 2023-03-28
Propriétaire Mydecine Innovations Group Inc ()
Classes de Nice  ?
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Biological research; Biological research and analysis; Biomedical research services; Chemical, biochemical, biological and bacteriological research and analysis; Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of pharmacogenetics; Development of pharmaceutical preparations and medicines; Genetic testing for scientific research purposes; Laboratory research in the field of mental health; Laboratory research in the field of mycology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of mental health; Medical and scientific research in the field of mycology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research services; Product research and development; Providing information about medical and scientific research; Providing information about medical research; Providing information about medical research in the field of mental health; Providing information about medical research in the field of mycology; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Quality control for others; Research and development in the field of mental health; Research and development in the field of mycology; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of technology in the field of mental health; Research and development of technology in the field of mycology; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific and technological services, namely, research and design in the field of mental health; Scientific and technological services, namely, research and design in the field of mycology; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mental health; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mycology; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research and development; Scientific research in the field of genetics and genetic engineering; Scientific research in the nature of conducting clinical trials for others in the field of mental health; Scientific research in the nature of conducting clinical trials for others in the field of mycology; Testing of pharmaceuticals Psychotherapy; Addiction treatment services; Advisory services relating to health care; Advisory services relating to health; Alternative medicine services; Clinical mental health counseling services; Consultancy services relating to health care; Drug use testing services; Health care; Health care consulting in the field of mental health; Health care services for treating mental health; Health care services, namely, providing a database in the field of mental health information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, providing a database in the field of mycology information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, pharmaceutical drug development services, medical research, biological research, product research and development and pharmaceutical research services; Health clinic services; Managed health care services; Medical services; Mental health services; Mental health therapy services; Providing mental health and wellness information; Psychotherapy services

29.

MYDECINE INNOVATIONS GROUP

      
Numéro de série 97289971
Statut Enregistrée
Date de dépôt 2022-03-01
Date d'enregistrement 2023-03-28
Propriétaire Mydecine Innovations Group Inc ()
Classes de Nice  ?
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Biological research; Biological research and analysis; Biomedical research services; Chemical, biochemical, biological and bacteriological research and analysis; Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of pharmacogenetics; Development of pharmaceutical preparations and medicines; Genetic testing for scientific research purposes; Laboratory research in the field of mental health; Laboratory research in the field of mycology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of mental health; Medical and scientific research in the field of mycology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research services; Product research and development; Providing information about medical and scientific research; Providing information about medical research; Providing information about medical research in the field of mental health; Providing information about medical research in the field of mycology; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Quality control for others; Research and development in the field of mental health; Research and development in the field of mycology; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of technology in the field of mental health; Research and development of technology in the field of mycology; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific and technological services, namely, research and design in the field of mental health; Scientific and technological services, namely, research and design in the field of mycology; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mental health; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mycology; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research and development; Scientific research in the field of genetics and genetic engineering; Scientific research in the nature of conducting clinical trials for others in the field of mental health; Scientific research in the nature of conducting clinical trials for others in the field of mycology; Testing of pharmaceuticals Psychotherapy; Addiction treatment services; Advisory services relating to health care; Advisory services relating to health; Alternative medicine services; Clinical mental health counseling services; Consultancy services relating to health care; Drug use testing services; Health care; Health care consulting in the field of mental health; Health care services for treating mental health; Health care services, namely, providing a database in the field of mental health information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, providing a database in the field of mycology information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, pharmaceutical drug development services, medical research, biological research, product research and development and pharmaceutical research services; Health clinic services; Managed health care services; Medical services; Mental health services; Mental health therapy services; Providing mental health and wellness information; Psychotherapy services

30.

M MYDECINE INNOVATIONS GROUP

      
Numéro de série 97289997
Statut Enregistrée
Date de dépôt 2022-03-01
Date d'enregistrement 2023-03-28
Propriétaire Mydecine Innovations Group Inc ()
Classes de Nice  ?
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Biological research; Biological research and analysis; Biomedical research services; Chemical, biochemical, biological and bacteriological research and analysis; Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of pharmacogenetics; Development of pharmaceutical preparations and medicines; Genetic testing for scientific research purposes; Laboratory research in the field of mental health; Laboratory research in the field of mycology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of mental health; Medical and scientific research in the field of mycology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research services; Product research and development; Providing information about medical and scientific research; Providing information about medical research; Providing information about medical research in the field of mental health; Providing information about medical research in the field of mycology; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Quality control for others; Research and development in the field of mental health; Research and development in the field of mycology; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of technology in the field of mental health; Research and development of technology in the field of mycology; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific and technological services, namely, research and design in the field of mental health; Scientific and technological services, namely, research and design in the field of mycology; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mental health; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mycology; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research and development; Scientific research in the field of genetics and genetic engineering; Scientific research in the nature of conducting clinical trials for others in the field of mental health; Scientific research in the nature of conducting clinical trials for others in the field of mycology; Testing of pharmaceuticals Psychotherapy; Addiction treatment services; Advisory services relating to health care; Advisory services relating to health; Alternative medicine services; Clinical mental health counseling services; Consultancy services relating to health care; Drug use testing services; Health care; Health care consulting in the field of mental health; Health care services for treating mental health; Health care services, namely, providing a database in the field of mental health information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, providing a database in the field of mycology information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, pharmaceutical drug development services, medical research, biological research, product research and development and pharmaceutical research services; Health clinic services; Managed health care services; Medical services; Mental health services; Mental health therapy services; Providing mental health and wellness information; Psychotherapy services

31.

M

      
Numéro de série 97290054
Statut Enregistrée
Date de dépôt 2022-03-01
Date d'enregistrement 2023-03-28
Propriétaire Mydecine Innovations Group Inc ()
Classes de Nice  ?
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Biological research; Biological research and analysis; Biomedical research services; Chemical, biochemical, biological and bacteriological research and analysis; Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of pharmacogenetics; Development of pharmaceutical preparations and medicines; Genetic testing for scientific research purposes; Laboratory research in the field of mental health; Laboratory research in the field of mycology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of mental health; Medical and scientific research in the field of mycology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research services; Product research and development; Providing information about medical and scientific research; Providing information about medical research; Providing information about medical research in the field of mental health; Providing information about medical research in the field of mycology; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Quality control for others; Research and development in the field of mental health; Research and development in the field of mycology; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of technology in the field of mental health; Research and development of technology in the field of mycology; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific and technological services, namely, research and design in the field of mental health; Scientific and technological services, namely, research and design in the field of mycology; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mental health; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mycology; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research and development; Scientific research in the field of genetics and genetic engineering; Scientific research in the nature of conducting clinical trials for others in the field of mental health; Scientific research in the nature of conducting clinical trials for others in the field of mycology; Testing of pharmaceuticals Psychotherapy; Addiction treatment services; Advisory services relating to health care; Advisory services relating to health; Alternative medicine services; Clinical mental health counseling services; Consultancy services relating to health care; Drug use testing services; Health care; Health care consulting in the field of mental health; Health care services for treating mental health; Health care services, namely, providing a database in the field of mental health information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, providing a database in the field of mycology information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, pharmaceutical drug development services, medical research, biological research, product research and development and pharmaceutical research services; Health clinic services; Managed health care services; Medical services; Mental health services; Mental health therapy services; Providing mental health and wellness information; Psychotherapy services

32.

MYDECINE HEALTH SCIENCES

      
Numéro de série 97267542
Statut Enregistrée
Date de dépôt 2022-02-15
Date d'enregistrement 2023-03-28
Propriétaire Mydecine Innovations Group Inc ()
Classes de Nice  ?
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Biological research; Biological research and analysis; Biomedical research services; Chemical, biochemical, biological and bacteriological research and analysis; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of pharmacogenetics; Consulting services in the field of biotechnology; Development of pharmaceutical preparations and medicines; Genetic testing for scientific research purposes; Laboratory research in the field of mental health; Laboratory research in the field of mycology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of mental health; Medical and scientific research in the field of mycology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research services; Product research and development; Providing information about medical research; Providing information about medical research in the field of mental health; Providing information about medical research in the field of mycology; Providing information about medical and scientific research; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Quality control for others; Research and development in the field of mental health; Research and development in the field of mycology; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of technology in the field of mental health; Research and development of technology in the field of mycology; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific and technological services, namely, research and design in the field of mental health; Scientific and technological services, namely, research and design in the field of mycology; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mental health; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mycology; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research and development; Scientific research in the field of genetics and genetic engineering; Testing of pharmaceuticals; Scientific research in the nature of conducting clinical trials for others in the field of mental health; Scientific research in the nature of conducting clinical trials for others in the field of mycology Addiction treatment services; Advisory services relating to health care; Advisory services relating to health; Alternative medicine services; Clinical mental health counseling services; Consultancy services relating to health care; Drug use testing services; Health care; Health care consulting in the field of mental health; Health care services for treating mental illnesses; Health care services, namely, providing a database in the field of mental health information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, providing a database in the field of mycology information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, pharmaceutical drug development services, medical research, biological research, product research and development and pharmaceutical research services; Health clinic services; Managed health care services; Medical services; Mental health services; Mental health therapy services; Providing mental health and wellness information; Psychotherapy; Psychotherapy services

33.

FUNGTIONAL

      
Numéro de série 90160986
Statut Enregistrée
Date de dépôt 2020-09-04
Date d'enregistrement 2021-08-10
Propriétaire Mydecine Innovations Group Inc ()
Classes de Nice  ?
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Genetic testing for scientific research purposes; Product research and development; Research and development of technology in the field of mycology; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific research and development Farming services in the field of fungi; Organic farming services in the field of fungi

34.

MYDECINE

      
Numéro de série 90020592
Statut Enregistrée
Date de dépôt 2020-06-25
Date d'enregistrement 2021-01-19
Propriétaire Mydecine Innovations Group Inc ()
Classes de Nice  ?
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Genetic testing for scientific research purposes; Product research and development; Research and development of vaccines and medicines; Research and development of technology in the field of mycology; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific research and development Farming services in the field of fungi; Organic farming services in the field of fungi